ERBB2 and breast cancer: A review aimed at identifying prognostic factors and survival parameters after developing bone radioiodine-resistant metastases (BM), together with the effects of combined therapies in patients with HER2+ breast cancer (BC), reported that a combination of trastuzumab and lapatinib therapy or trastuzumab and pertuzumab therapy had the longest median survival compared with other therapies [20].